Sign in
TerminatedPhase 3

Efficacy of CLORazepate for the Treatment of MIGraine Attack in the Emergency Room

Key facts

Who runs it
Assistance Publique - Hôpitaux de Paris
Where
France1 site in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
Phase
Phase 3
People taking part
323 people enrolled
Started
8 Jul 2021
Ended
10 Apr 2024
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Clorazepate Dipotassium
  • Placebo
  • Ketoprofen
  • Metoclopramide
Record updated
8 September 2025
Why it stopped
It has been determined that continuing with enrollments in this study is no longer justified due to the lack of significant impact on the expected outcomes.

Who can take part

Age
18 years to 70 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • Age from 18 to 70
  • Patient suffering migraine or probable migraine (diagnosis made by neurologist according to IHCD3)
  • Present migraine attack lasting ≤ 72 hours
  • Headache intensity moderate or severe on the verbal ordinal scale (4 levels: no headache, mild, moderate or severe)
  • Patient requiring parenteral treatment
  • Affiliation to the French Health-care System "sécurité sociale"

Who cannot take part

  • Patient requiering treatment with sumatriptan SC, particularly in the event of failure of an anti-inflammatory drug at an effective dose taken within 6 hours
  • contraindication to any of the investigational medication
  • previous participation to this study
  • abnormalities of neurological exam, seizure, fever (≥ 38°C), and/or SBP≥180 and/or DBP≥110 mmHg
  • known respiratory or liver insufficiency
  • suspicion of secondary headache
  • inability to understand the consent or scales
  • pregnancy or breast-feeding
  • acute alcohol consumption or alcoholism
  • myasthenia
  • recent use of benzodiazepines (< 24h diazepam, clonazepam, clorazepate ; < 6h alprazolam, lorazepam, midazolam)
  • recent use of pain killers (< 2h)
  • contraindication to intravenous access

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The purpose of this study is to evaluate the efficacy of clorazepate in addition to the usual medication for treating migraine attack in the emergency room

The 2 groups in the trial

  • Control armPlacebo, for comparison

    placebo and standard care : * Placebo IV * Ketoprofen 100 mg IV (if nausea-vomiting) * Metoclopramide 10 mg IV(if nausea-vomiting)

    Treatment: Placebo, Ketoprofen, and Metoclopramide

  • Experimental armTreatment being tested

    clorazepate and standard care : * Clorazepate 20 mg IV * Ketoprofen 100 mg IV (if nausea-vomiting) * Metoclopramide 10 mg IV(if nausea-vomiting)

    Treatment: Clorazepate Dipotassium, Ketoprofen, and Metoclopramide

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Randomized Double Blinded Monocentric Study Evaluating the Efficacy of CLORazepate for the Treatment of MIGraine Attack in the Emergency Room
Record updated
8 September 2025